Biotinylated Human BTN3A2 Protein, His,Avitag?
分子別名（Synonym）
BTN3A2,BT3.2
表達區(qū)間及表達系統(tǒng)（Source）
Biotinylated Human BTN3A2, His,Avitag (BT2-H82E7) is expressed from human 293 cells (HEK293). It contains AA Gln 30 - Trp 248 (Accession # P78410-1).
Predicted N-terminus: Gln30
蛋白結(jié)構(gòu)（Molecular Characterization）
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag?).
The protein has a calculated MW of 27.3 kDa. The protein migrates as 30-33 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
標記（Biotinylation）
Biotinylation of this product is performed using Avitag? technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
蛋白標記度（Biotin:Protein Ratio)
Passed as determined by the HABA assay / binding ELISA.
內(nèi)毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
純度（Purity）
>95% as determined by SDS-PAGE.
制劑（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
重構(gòu)方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景（Background）
腫瘤細胞表達的親丁蛋白亞家族3成員A2（BTN3A2/BT3.2）mRNA先前被鑒定為高級別漿液性上皮性卵巢癌癥（HG-EOC）小隊列中的預后因素。我們發(fā)現(xiàn)三種BTN3A亞型：BTN3A1、BTN3A2和BTN3A3與B7超家族的蛋白質(zhì)具有高度的結(jié)構(gòu)同源性，在溶液中以V形同源二聚體存在，通過膜近端C型Ig結(jié)構(gòu)域結(jié)合。
關鍵字： BTN3A2;BTN3A2蛋白;BTN3A2重組蛋白;ACRO;百普賽斯;
百普賽斯集團ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領域提供關鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個城市設有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關系。集團旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學等。